Amgen Inc
USUSDAmgen Inc (MX:AMGN) — Biotechnology: Biological Products (No Diagnostic Substances). Antal børser, hvor selskabets aktier handles: 4. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om Virksomheden
- Websted
- amgen.com
- Investorrelationer
- investors.amgen.com/
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Hovedkontor
- Thousand Oaks, United States
- Administrerende Direktør
- Robert A. Bradway
- Ansatte
- 17 900
- Grundlagt
- 1980
- Børsnoteret Siden
- 29.02.2008 (MX:AMGN)
- Udestående Aktier
- 540.63 mio. pr. 2026-07-30
- Free Float
- 539.16 mio.
- Markedsværdi
- 226.05 mia. USD
- Insidere
- 0.23%
- Institutionelle Investorer
- 85.02%
- Branche (SIC)
- Biological Products, (No Diagnostic Substances)
- Juridisk Form
- XTIQ
- ISIN
- US0311621009
- LEI
- 62QBXGPJ34PQ72Z12S66
- Udbetalingsgrad
- 60.4%
- FCF
- 10.2 mia. USD52%
- Gæld
- 57.3 mia. USD4.3 år FCF
- Udbyttestreak
- 15 år
- Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 30.06.2026 (selskabets seneste rapport).
Beskrivelse
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Børser og Tickere
| Børs | Ticker | Valuta | Pris | Type |
|---|---|---|---|---|
| US USA Stocks | AMGN primær | USD | 414.87 +1.82% | almindelige aktier |
| HK Hong Kong Stock Exchange | 4332 sekundær | HKD | — | |
| LSE London Stock Exchange | 0R0T IOB | USD | 411.854 +1.17% | almindelige aktier |
| MX Mexican Stock Exchange | AMGN sekundær | MXN | 7 500.0098 +0.00% | almindelige aktier |
| XETRA Xetra | AMG sekundær | EUR | 367.95 -1.39% | almindelige aktier |
Udbytte
Amgen Inc (AMGN) udbetaler udbytte kvartalsvis. Pr. År (12 måneder op til og med den senest annoncerede betaling): 180.7291 MXN pr. Aktie (betalinger: 4). Det svarer til cirka 2.41% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 20.11.2026. Uafbrudt udbyttehistorik: 15 år.
| Ex-Dato | Udbetaling | Beløb | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-08-21 | — | 45.8186 MXN | 0.6/2.4 % | kvartalsvis | MX:AMGN |
| 2026-05-15 | — | 45.8186 MXN | 0.6/2.4 % | kvartalsvis | MX:AMGN |
| 2026-02-13 | — | 45.8186 MXN | 0.6/2.3 % | kvartalsvis | MX:AMGN |
| 2025-11-21 | — | 43.2732 MXN | 0.6/2.3 % | kvartalsvis | MX:AMGN |
| 2025-08-22 | — | 43.2732 MXN | 0.6/2.3 % | kvartalsvis | MX:AMGN |
| 2025-05-16 | — | 43.2732 MXN | 0.6/2.2 % | kvartalsvis | MX:AMGN |
| 2025-02-14 | — | 43.2732 MXN | 0.6/2.2 % | kvartalsvis | MX:AMGN |
| 2024-11-19 | — | 40.9095 MXN | 0.5/2.2 % | kvartalsvis | MX:AMGN |
| 2024-08-16 | — | 40.9095 MXN | 0.5/2.2 % | kvartalsvis | MX:AMGN |
| 2024-05-16 | — | 40.9095 MXN | 0.5/2.1 % | kvartalsvis | MX:AMGN |
| 2024-02-15 | — | 40.9095 MXN | 0.5/2.1 % | kvartalsvis | MX:AMGN |
| 2023-11-16 | — | 38.7277 MXN | 0.5/2.1 % | kvartalsvis | MX:AMGN |
| 2023-08-17 | — | 38.7277 MXN | 0.5/2.0 % | kvartalsvis | MX:AMGN |
| 2023-05-17 | — | 38.7277 MXN | 0.5/2.0 % | kvartalsvis | MX:AMGN |
| 2023-02-14 | — | 38.7277 MXN | 0.5/1.9 % | kvartalsvis | MX:AMGN |
| 2022-11-16 | — | 35.2731 MXN | 0.5/1.9 % | kvartalsvis | MX:AMGN |
| 2022-08-17 | — | 35.2731 MXN | 0.5/1.8 % | kvartalsvis | MX:AMGN |
| 2022-05-16 | — | 35.2731 MXN | 0.5/1.4 % | kvartalsvis | MX:AMGN |
| 2022-02-14 | — | 35.2731 MXN | 0.5/0.9 % | kvartalsvis | MX:AMGN |
| 2021-11-16 | — | 32.0003 MXN | 0.4/0.4 % | kvartalsvis | MX:AMGN |
Største Ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| Blackrock Inc. | 9.13% | 49.36 mio. | 2026-06-30 |
| Vanguard Capital Managem… | 6.52% | 35.25 mio. | 2026-06-30 |
| State Street Corporation | 5.65% | 30.56 mio. | 2026-06-30 |
| Capital World Investors | 5.38% | 29.08 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 17.13 mio. | 2026-06-30 |
| Invesco Ltd. | 3.02% | 16.32 mio. | 2026-06-30 |
| Geode Capital Management… | 2.9% | 15.7 mio. | 2026-06-30 |
| Charles Schwab Investmen… | 2.78% | 15.03 mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.75% | 14.85 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 13.99 mio. | 2026-06-30 |
| Morgan Stanley | 2.53% | 13.65 mio. | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.15% | 11.61 mio. | 2026-08-31 |
| SCHWAB STRATEGIC TRUST-S… | 1.81% | 9.79 mio. | 2026-05-31 |
| Income Fund of America | 1.44% | 7.76 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 7.28 mio. | 2026-07-31 |
| Wells Fargo & Company | 1.34% | 7.24 mio. | 2026-06-30 |
| AMERICAN BALANCED FUND | 1.31% | 7.09 mio. | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 6.98 mio. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 6.6 mio. | 2026-08-31 |
| WASHINGTON MUTUAL INVEST… | 1.16% | 6.27 mio. | 2026-06-30 |
| BRADWAY ROBERT A (Chief… | ≈0.12% | 657 299 | 2026-05-05 |
| SANTOS ESTEBAN (Officer) | ≈0.02% | 84 279 | 2026-05-05 |
| GORDON MURDO (Officer) | ≈0.01% | 51 837 | 2026-05-05 |
| GRIFFITH PETER H. (Chief… | ≈0.01% | 50 706 | 2026-05-05 |
| REESE DAVID M. (Chief Te… | ≈0.01% | 42 812 | 2026-05-05 |
| GRAHAM JONATHAN P (Gener… | ≈0.01% | 40 211 | 2026-05-05 |
| BRADNER JAMES E. (Office… | ≈0.01% | 30 462 | 2026-05-05 |
| ECKERT ROBERT ANDREW (Di… | ≈0% | 26 251 | 2026-05-19 |
| JACKS TYLER (Director) | ≈0% | 18 284 | 2026-05-19 |
| KULLMAN ELLEN JAMISON (D… | ≈0% | 14 536 | 2026-05-19 |
